Live attenuated influenza vaccine

摘要: The development of the live, attenuated influenza vaccine (LAIV), based on cold-adapted (ca), ca A/Ann Arbor/6/60 and B/Ann Arbor/1/66 backbones, has spanned several decades. contains three strains, two A strains one B strain; these are genetic reassortants, each harboring gene segments from currently circulating wild type virus conferring appropriate antigens (e.g., A/H3N2, A/H1N1 or B) remaining six donor virus. Both viruses have complex signatures that control key biological traits resulting including temperature-sensitivity in vitro attenuation an animal model, overall vaccine. Studies humans demonstrated can elicit humoral antibodies as well cellular immunity; both responses generally more readily detectable children than adults. number different clinical studies adults shown this reduce burden illness vaccinated subjects, seasons which strain antigenically drifted included These attributes live vaccine, others ability to produce substantially doses per egg inactivated make it a potentially useful platform generate effective combat annual seasonal future pandemics.